Overview
POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIU
Status:
Active, not recruiting
Active, not recruiting
Trial end date:
2025-04-30
2025-04-30
Target enrollment:
Participant gender: